Health Care • Biotechnology: Laboratory Analytical Instruments
$19.35 ▲ +0.67
(+3.59%)
MKT CAP: $34.6M • VOL: 11.0K
52W L $18 52W H $34
PRPO // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $24.2M | $18.6M | $15.4M |
| YoY Revenue Growth % | +30.5% | +20.5% | — |
| Gross Profit | $10.7M | $7.6M | — |
| Gross Margin % | 44.2% | 40.7% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$1.2M | -$4.2M | -$7.6M |
| Operating Margin % | -5.0% | -22.7% | -49.4% |
| Net Income (GAAP) | -$363.0K | -$4.3M | -$5.9M |
| EBITDA (Normalized) | -$941.2K | -$4.0M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $685.0K | $439.0K | -$3.6M |
| Capital Expenditures (CapEx) | $326.0K | $223.0K | — |
| Free Cash Flow (FCF) | $359.0K | $216.0K | -$3.6M |
| FCF Margin % | 1.5% | 1.2% | -23.1% |
| Return on Invested Capital (ROIC %) | -7.9% | -30.9% | — |
| Cash & Short-Term Equivalents | $2.7M | $1.4M | — |
| Total Debt (Short + Long Term) | $47.0K | $77.0K | — |
| Total Stockholders' Equity | $14.6M | $12.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR PRPO.